Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 12;47(5):353.
doi: 10.3390/cimb47050353.

Differential Profiles of Gut Microbiota-Derived Metabolites of Bile Acids and Propionate as Potential Predictors of Depressive Disorder in Women with Morbid Obesity at High Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease-A Pilot Study

Affiliations

Differential Profiles of Gut Microbiota-Derived Metabolites of Bile Acids and Propionate as Potential Predictors of Depressive Disorder in Women with Morbid Obesity at High Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease-A Pilot Study

Joanna Michalina Jurek et al. Curr Issues Mol Biol. .

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver condition linked to cardiometabolic diseases and mental health issues, with studies highlighting disruptions in gut microbiota activity, including bile acid (BA) metabolism. Therefore, the main aim of this exploratory analysis was to assess microbiota-derived metabolites, specifically BAs and short-chain fatty acids (SCFAs), as potential biomarkers of depressive disorder (DD) in women with morbid obesity at MASLD risk. In this pilot study, 33 females with morbid obesity who were scheduled for bariatric surgery were evaluated. Medical and clinical data were collected, and microbial metabolites from pre-surgery blood samples were analyzed. Patients were stratified according to the presence of DD. Analysis with Spearman's rank test was used to assess correlations and logistic regression models were built to evaluate biomarkers as predictors of DD risk using both receiver operating characteristic (ROC) and precision-recall curves. In this cohort, 30.3% of females were reported to have DD, in addition to significantly elevated levels of certain BAs and SCFAs, including glycodeoxycholic acid (GDCA) and propionate, which were also correlated with some metabolic biomarkers. However, there were no differences in the incidence of MASLD or metabolic syndrome between patients with DD or without. In conclusion, microbiota-derived metabolites such as GDCA and propionate may influence DD risk in females with morbid obesity; however, their potential use as predictive biomarkers should be further investigated to confirm their role in psycho-metabolic conditions.

Keywords: bile acids; depression; metabolic dysfunction-associated steatotic liver disease; microbial metabolites; obesity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Significant changes in levels of microbiota-derived metabolites (A) GCA, (B) GDCA, and (C) propionate between control group (CN) and depression disorder cohort (DD). p values were calculated by using ANCOVA, adjusting for type 2 diabetes diagnosis, and by multiple comparisons with Benjamini–Hochberg method. p < 0.05 was considered statistically significant.
Figure 2
Figure 2
Partial correlations between bile acids (BAs), short-chain fatty acids (SCFAs), and other microbial bioactives and the clinical and biochemical characteristics of the study cohort (using diabetes mellitus as a covariate). Spearman’s rank coefficient is displayed only in the cases of significant (p value < 0.05) associations. CDCA, Chenodeoxycholic acid; DCA, Deoxycholic acid; GCDCA, Glycochenodeoxycholic acid; GCA, Glycocholic acid; GDCA, Glycodeoxycholic acid; TCLA, Taurochenodeoxycholic acid; TCDCA, Taurochenodeoxycholic acid; TDCA, Taurodeoxycholic acid; TUDCA, Tauroursodeoxycholic acid; GLCA, Glycolithocholic acid; GUDCA, Glycoursodeoxycholic acid; TMA, Trimethylamine; TMAO, Trimethylamine N-oxide; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA1-IR, homeostatic model assessment method–insulin resistance; HbA1c, glycosylated hemoglobin; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; ALP, alkaline phosphatase; LDH, Lactate Dehydrogenase; CRP, C-reactive protein. All BAs are measured as nM; SCFAs are measured as ng/mL;TMA determined as nM. Choline, TMAO, and betaine are measured as uM.
Figure 3
Figure 3
ROC curve and precision–recall curve for microbial metabolites. (A) ROC curve for glycodeoxycholic acid (GDCA), the bile acid (BAs) selected by the best-fit method, in a logistic regression model predicting depression disorder (DD) in a cohort of females with morbid obesity. (B) Precision–recall curve for glycodeoxycholic acid (GDCA), the bile acid (BAs) selected by the best-fit method, in a logistic regression model predicting depression disorder (DD) in a cohort of females with morbid obesity. The dashed diagonal line in the ROC plot represents the performance of a random classifier (AUC = 0.5).
Figure 4
Figure 4
ROC curve and precision–recall curve for propionate. (A) ROC curve for propionate, the predictor selected by the best-fit method among all measured variables in a logistic regression model predicting depression disorder (DD) in a cohort of females with morbid obesity. (B) Precision–recall curve for propionate, the predictor selected by the best-fit method among all measured variables in a logistic regression model predicting depression disorder (DD) in a cohort of females with morbid obesity. The dashed diagonal line in the ROC plot represents the performance of a random classifier (AUC = 0.5).

Similar articles

References

    1. Chan W.-K., Chuah K.-H., Rajaram R.B., Lim L.-L., Ratnasingam J., Vethakkan S.R. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J. Obes. Metab. Syndr. 2023;32:197–213. doi: 10.7570/jomes23052. - DOI - PMC - PubMed
    1. Targher G., Byrne C.D., Tilg H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691–702. doi: 10.1136/gutjnl-2023-330595. - DOI - PubMed
    1. Hashimoto K. Gut–microbiota–brain axis by bile acids in depression. Psychiatry Clin. Neurosci. 2022;76:281. doi: 10.1111/pcn.13370. - DOI - PubMed
    1. Youssef N.A., Abdelmalek M.F., Binks M., Guy C.D., Omenetti A., Smith A.D., Diehl A.M.E., Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int. 2013;33:1062–1070. doi: 10.1111/liv.12165. - DOI - PubMed
    1. Xiao J., Lim L.K.E., Ng C.H., Tan D.J.H., Lim W.H., Ho C.S.H., Tan E.X.X., Sanyal A.J., Muthiah M.D. Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease. Front. Med. 2021;8:691696. doi: 10.3389/fmed.2021.691696. - DOI - PMC - PubMed

LinkOut - more resources